Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate
- PMID: 6931470
- DOI: 10.1111/j.1600-0447.1980.tb07080.x
Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. I. A one year double-blind study of clopenthixol decanoate and flupenthixol palmitate
Abstract
Clopenthixol decanoate and flupenthixol palmitate, both depot neuroleptics belonging to the thioxanthene group, were studied during double-blind conditions for 12 months using four week intervals between injections. The 60 patients included in the study were chronic schizophrenics and treated as outpatients after earlier admission to hospital and rehabilitation training periods. They had all been treated with depot neuroleptics in the last three years and they had been free from relapse for at least 15 months. The main aim with this trial was to study the two depot drugs during maintenance treatment conditions in an outpatient setting. Ten patients dropped out, 7 because of unsatisfactory effect, mainly because only limited dose levels were accepted according to the design. In spite of the earlier long lasting neuroleptic treatment and the good social adaptation in this schizophrenic subgroup there was observed a symptom decrease in all the rating scales even in these symptom poor patients. This improvement in psychopathology with optimal results after half a year seems to be a combined result of the efficient neuroleptics tested and careful monitoring of the drug.
Similar articles
-
Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. II. Factor analysis of the CPRS sub-scale for schizophrenia.Acta Psychiatr Scand Suppl. 1980;279:29-40. doi: 10.1111/j.1600-0447.1980.tb07081.x. Acta Psychiatr Scand Suppl. 1980. PMID: 6931471
-
Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome.Acta Psychiatr Scand Suppl. 1980;279:55-63. doi: 10.1111/j.1600-0447.1980.tb07083.x. Acta Psychiatr Scand Suppl. 1980. PMID: 6931473
-
Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study.Acta Psychiatr Scand Suppl. 1980;279:64-76. doi: 10.1111/j.1600-0447.1980.tb07084.x. Acta Psychiatr Scand Suppl. 1980. PMID: 6105763
-
Clinical pharmacokinetics of the depot antipsychotics.Clin Pharmacokinet. 1985 Jul-Aug;10(4):315-33. doi: 10.2165/00003088-198510040-00003. Clin Pharmacokinet. 1985. PMID: 2864156 Review.
-
Depot neuroleptics in relapse prevention: advantages and disadvantages.Int Clin Psychopharmacol. 1995 Jan;9 Suppl 5:17-20. doi: 10.1097/00004850-199501005-00004. Int Clin Psychopharmacol. 1995. PMID: 7622829 Review.
Cited by
-
Zuclopenthixol dihydrochloride for schizophrenia.Cochrane Database Syst Rev. 2017 Nov 16;11(11):CD005474. doi: 10.1002/14651858.CD005474.pub2. Cochrane Database Syst Rev. 2017. PMID: 29144549 Free PMC article.
-
An open trial of zuclopenthixol in management of acute psychoses : a multicentered study.Indian J Psychiatry. 1999 Jul;41(3):242-8. Indian J Psychiatry. 1999. PMID: 21455397 Free PMC article.
-
Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD001470. doi: 10.1002/14651858.CD001470.pub2. Cochrane Database Syst Rev. 2014. PMID: 24915451 Free PMC article.
-
Depot haloperidol decanoate for schizophrenia.Cochrane Database Syst Rev. 2000;1999(2):CD001361. doi: 10.1002/14651858.CD001361. Cochrane Database Syst Rev. 2000. PMID: 10796438 Free PMC article.
-
Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses.Cochrane Database Syst Rev. 2000;1999(2):CD001164. doi: 10.1002/14651858.CD001164. Cochrane Database Syst Rev. 2000. PMID: 10796607 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical